Clinical Trial

PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 24, 2025 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
Evaluate the safety and efficacy of PD-1 antibody Carilizumab combined with apatinib for the conversion therapy of unresectable stage III and IV dMMR gastric cancer.
Trial Details
NCT Number NCT06792162
Lead Sponsor Peking University Third Hospital
Conditions Gastric Cancer
Enrollment 20 participants
Start Date 2023-04-20
Primary Completion 2026-04 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2025-01-24